In silico investigation of binding propensity of hematoxylin derivative and damnacanthal for their potential inhibitory effect on HIV-1 Vpr from different subtypes

References

• Abecasis, A. B., Wensing, A. M., Paraskevis, D., Vercauteren, J., Theys, K., Van de Vijver, D. A., Albert, J., Asjö, B., Balotta, C., Beshkov, D., Camacho, R. J., Clotet, B., De Gascun, C., Griskevicius, A., Grossman, Z., Hamouda, O., Horban, A., Kolupajeva, T., Korn, K., … Vandamme, A.-M. (2013). HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics. Retrovirology, 10(1), 7. https://doi.org/10.1186/1742-4690-10-7
   PubMedGoogle Scholar
• Abongwa, L. E., Nyamache, A. K., Torimiro, J. N., Okemo, P., & Charles, F. (2019). Human immunodeficiency virus type 1 (HIV-1) subtypes in the northwest region, Cameroon. Virology Journal, 16(1), 103. https://doi.org/10.1186/s12985-019-1209-6
   PubMed Web of Science ®Google Scholar
• Adamson, C. S., & Freed, E. O. (2009). Anti-HIV-1 therapeutics: From FDA-approved drugs to hypothetical future targets. Molecular Interventions, 9(2), 70–74. https://doi.org/10.1124/mi.9.2.5
   PubMedGoogle Scholar
• Addo, M. M., Altfeld, M., Rosenberg, E. S., Eldridge, R. L., Philips, M. N., Habeeb, K., Khatri, A., Brander, C., Robbins, G. K., Mazzara, G. P., Goulder, P. J. R., Walker, B. D., & the HIV Controller Study Collaboration. (2001). The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals. Proceedings of the National Academy of Sciences of the United States of America, 98(4), 1781–1786. https://doi.org/10.1073/pnas.98.4.1781
   PubMed Web of Science ®Google Scholar
• Arkin, M. R., Tang, Y., & Wells, J. A. (2014). Small-molecule inhibitors of protein-protein interactions: Progressing toward the reality. Chemistry & Biology, 21(9), 1102–1114. https://doi.org/10.1016/j.chembiol.2014.09.001
   PubMedGoogle Scholar
• Arts, E. J., & Hazuda, D. J. (2012). HIV-1 antiretroviral drug therapy. Cold Spring Harbor Perspectives in Medicine, 2(4), a007161. https://doi.org/10.1101/cshperspect.a007161
   PubMed Web of Science ®Google Scholar
• Baker, N. A., Sept, D., Joseph, S., Holst, M. J., & McCammon, J. A. (2001). Electrostatics of nanosystems: Application to microtubules and the ribosome. Proceedings of the National Academy of Sciences of the United States of America, 98(18), 10037–10041.
   PubMed Web of Science ®Google Scholar
• Barouch, D. H. (2008). Challenges in the development of an HIV-1 vaccine. Nature, 455(7213), 613–619. https://doi.org/10.1038/nature07352
   PubMed Web of Science ®Google Scholar
• Bbosa, N., Kaleebu, P., & Ssemwanga, D. (2019). HIV subtype diversity worldwide. Current Opinion in HIV and AIDS, 14(3), 153–160. https://doi.org/10.1097/COH.0000000000000534
   PubMed Web of Science ®Google Scholar
• Bjelkmar, P., Larsson, P., Cuendet, M. A., Hess, B., & Lindahl, E. (2010). Implementation of the CHARMM force field in GROMACS: Analysis of protein stability effects from correction maps, virtual interaction sites, and water models. Journal of Chemical Theory and Computation, 6(2), 459–466. https://doi.org/10.1021/ct900549r
   PubMed Web of Science ®Google Scholar
• Brenke, R., Kozakov, D., Chuang, G. Y., Beglov, D., Hall, D., Landon, M. R., Mattos, C., & Vajda, S. (2009). Fragment-based identification of druggable 'hot spots’ of proteins using Fourier domain correlation techniques. Bioinformatics (Oxford, England), 25(5), 621–627. https://doi.org/10.1093/bioinformatics/btp036
   PubMed Web of Science ®Google Scholar
• Chaplin, B., Eisen, G., Idoko, J., Onwujekwe, D., Idigbe, E., Adewole, I., Gashau, W., Meloni, S., Sarr, A. D., Sankalé, J. L., Ekong, E., Murphy, R. L., & Kanki, P. (2011). Impact of HIV type 1 subtype on drug resistance mutations in Nigerian patients failing first-line therapy. AIDS Research and Human Retroviruses, 27(1), 71–80. https://doi.org/10.1089/aid.2010.0050
   PubMed Web of Science ®Google Scholar
• Corpet, F. (1988). Multiple sequence alignment with hierarchical clustering. Nucleic Acids Research, 16(22), 10881–10890. https://doi.org/10.1093/nar/16.22.10881
   PubMed Web of Science ®Google Scholar
• Darden, T., York, D., & Pedersen, L. (1998). Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems. Journal of Chemical Physics. 98(12), 10089–10092. https://doi.org/10.1063/1.464397
   Google Scholar
• Drew, E. D., & Janes, R. W. (2020). Identification of a druggable binding pocket in the spike protein reveals a key site for existing drugs potentially capable of combating Covid-19 infectivity. BMC Molecular and Cell Biology, 21(1), 49. https://doi.org/10.1186/s12860-020-00294-x
   PubMed Web of Science ®Google Scholar
• Dunne, M. (2007). Antiretroviral drug development: The challenge of cost and access. AIDS, 21(Suppl 4), S73–S79. https://doi.org/10.1097/01.aids.0000279709.47298.8a
   PubMedGoogle Scholar
• Eberhardt, J., Santos-Martins, D., Tillack, A. F., & Forli, S. (2021). AutoDock Vina 1.2.0: New docking methods, expanded force field, and python bindings. Journal of Chemical Information and Modeling, 61(8), 3891–3898. https://doi.org/10.1021/acs.jcim.1c00203
   PubMed Web of Science ®Google Scholar
• Engelman, A., & Cherepanov, P. (2012). The structural biology of HIV-1: Mechanistic and therapeutic insights. Nature Reviews. Microbiology, 10(4), 279–290. https://doi.org/10.1038/nrmicro2747
   PubMed Web of Science ®Google Scholar
• Gatell, J. M. (2011). Antiretroviral therapy for HIV: Do subtypes matter? Clinical Infectious Diseases, 53(11), 1153–1155. https://doi.org/10.1093/cid/cir686
   PubMed Web of Science ®Google Scholar
• Genheden, S., & Ryde, U. (2015). The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opinion on Drug Discovery, 10(5), 449–461. https://doi.org/10.1517/17460441.2015.1032936
   PubMed Web of Science ®Google Scholar
• Geretti, A. M., Harrison, L., Green, H., Sabin, C., Hill, T., Fearnhill, E., Pillay, D., Dunn, D., & On behalf of the UK Collaborative Group on HIV Drug Resistance and the UK Collaborative HIV Cohort Study. (2009). Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. Clinical Infectious Diseases, 48(9), 1296–1305. https://doi.org/10.1086/598502
   PubMed Web of Science ®Google Scholar
• German Advisory Committee Blood (Arbeitskreis Blut), Subgroup ‘Assessment of Pathogens Transmissible by Blood’. (2016). Human immunodeficiency virus (HIV). Transfusion Medicine and Hemotherapy, 43(3), 203–222. https://doi.org/10.1159/000445852
   PubMed Web of Science ®Google Scholar
• Golmohammadi, R., Baesi, K., Moradi, A., Farrokhi, M., McFarland, W., & Parsamajd, S. (2017). The first characterization of HIV-1 subtypes and drug resistance mutations among antiretrovirally treated patients in Kermanshah, Iran. Intervirology, 60(1–2), 33–37. https://doi.org/10.1159/000478701
   PubMed Web of Science ®Google Scholar
• Golo, V. L., & Shaĭtan, K. V. (2002). Dynamic attractor for the Berendsen thermostat an the slow dynamics of biomacromolecules. Biofizika, 47(4), 611–617.
   PubMed Web of Science ®Google Scholar
• González, M. E. (2017). The HIV-1 Vpr protein: A multifaceted target for therapeutic intervention. International Journal of Molecular Sciences, 18(1), 126. https://doi.org/10.3390/ijms18010126
   PubMed Web of Science ®Google Scholar
• Guenzel, C. A., Hérate, C., & Benichou, S. (2014). HIV-1 Vpr—A still “enigmatic multitasker”. Frontiers in Microbiology, 5, 127. https://doi.org/10.3389/fmicb.2014.00127
   PubMed Web of Science ®Google Scholar
• Guilloux, V. L., Schmidtke, P., & Tuffery, P. (2009). Fpocket: An open source platform for ligand pocket detection. BMC Bioinformatics, 10, 168. https://doi.org/10.1186/1471-2105-10-168
   PubMed Web of Science ®Google Scholar
• Hagiwara, K., Ishii, H., Murakami, T., Takeshima, S.-n., Chutiwitoonchai, N., Kodama, E. N., Kawaji, K., Kondoh, Y., Honda, K., Osada, H., Tsunetsugu-Yokota, Y., Suzuki, M., & Aida, Y. (2015). Synthesis of a Vpr-binding derivative for use as a novel HIV-1 inhibitor. PLoS One, 10(12), e0145573. https://doi.org/10.1371/journal.pone.0145573
   PubMed Web of Science ®Google Scholar
• Izadi, S., Anandakrishnan, R., & Onufriev, A. V. (2014). Building water models: A different approach. The Journal of Physical Chemistry Letters, 5(21), 3863–3871. https://doi.org/10.1021/jz501780a
   PubMed Web of Science ®Google Scholar
• Kamata, M., Wu, R. P., An, D. S., Saxe, J. P., Damoiseaux, R., Phelps, M. E., Huang, J., & Chen, I. S. (2006). Cell-based chemical genetic screen identifies damnacanthal as an inhibitor of HIV-1 Vpr induced cell death. Biochemical and Biophysical Research Communications, 348(3), 1101–1106. https://doi.org/10.1016/j.bbrc.2006.07.158
   PubMed Web of Science ®Google Scholar
• Kantor, R., & Katzenstein, D. (2004). Drug resistance in non-subtype B HIV-1. Journal of Clinical Virology, 29(3), 152–159. https://doi.org/10.1016/S1386-6532(03)00115-X
   PubMed Web of Science ®Google Scholar
• Kantor, R., Katzenstein, D. A., Efron, B., Carvalho, A. P., Wynhoven, B., Cane, P., Clarke, J., Sirivichayakul, S., Soares, M. A., Snoeck, J., Pillay, C., Rudich, H., Rodrigues, R., Holguin, A., Ariyoshi, K., Bouzas, M. B., Cahn, P., Sugiura, W., Soriano, V., … Shafer, R. W. (2005). Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. PLoS Medicine, 2(4), e112. https://doi.org/10.1371/journal.pmed.0020112
   PubMed Web of Science ®Google Scholar
• Kogan, M., & Rappaport, J. (2011). HIV-1 accessory protein Vpr: Relevance in the pathogenesis of HIV and potential for therapeutic intervention. Retrovirology, 8, 25. https://doi.org/10.1186/1742-4690-8-25
   PubMed Web of Science ®Google Scholar
• Kozakov, D., Grove, L. E., Hall, D. R., Bohnuud, T., Mottarella, S. E., Luo, L., Xia, B., Beglov, D., & Vajda, S. (2015). The FTMap family of web servers for determining and characterizing ligand-binding hot spots of proteins. Nature Protocols, 10(5), 733–755. https://doi.org/10.1038/nprot.2015.043
   PubMed Web of Science ®Google Scholar
• Kumari, R., Kumar, R., Lynn, A., & Open Source Drug Discovery Consortium. (2014). g_mmpbsa—A GROMACS tool for high-throughput MM-PBSA calculations. Journal of Chemical Information and Modeling, 54(7), 1951–1962. https://doi.org/10.1021/ci500020m
   PubMed Web of Science ®Google Scholar
• Lau, K. A., & Wong, J. J. (2013). Current trends of HIV recombination worldwide. Infectious Disease Reports, 5(Suppl 1), e4. https://doi.org/10.4081/idr.2013.s1.e4
   PubMedGoogle Scholar
• Li, G., & Clercq, E. D. (2021). Chapter 1: Overview of antiviral drug discovery and development: Viral versus host targets. In Cesar Munoz-Fontela and Rafael Delgado (Eds.), Antiviral discovery for highly pathogenic emerging viruses (pp. 1–27). The Royal Society of Chemistry. https://doi.org/10.1039/9781788016858-00001
   Google Scholar
• Lindahl, E., Abraham, M. J., Hess, B., & van der Spoel, D. (2021a). GROMACS 2020.5 Manual (2020.5). Zenodo. https://doi.org/10.5281/zenodo.4420784
   Google Scholar
• Lindahl, E., Abraham, M. J., Hess, B., & van der Spoel, D. (2021b). GROMACS 2020.5 Source code (2020.5). Zenodo. https://doi.org/10.5281/zenodo.4420785
   Google Scholar
• Lu, X., Zhao, H., Zhang, Y., Wang, W., Zhao, C., Li, Y., Ma, L., Cui, Z., & Chen, S. (2017). HIV-1 drug-resistant mutations and related risk factors among HIV-1-positive individuals experiencing treatment failure in Hebei Province, China. AIDS Research and Therapy, 14(1), 4. https://doi.org/10.1186/s12981-017-0133-3
   PubMedGoogle Scholar
• Majumder, S., & Giri, K. (2021). An insight into the binding mechanism of Viprinin and its morpholine and piperidine derivatives with HIV-1 Vpr: Molecular dynamics simulation, principal component analysis and binding free energy calculation study. Journal of Biomolecular Structure and Dynamics, 40(21), 10918–10930. https://doi https://doi.org/10.1080/07391102.2021.1954553
   PubMed Web of Science ®Google Scholar
• Mazzuti, L., Melengu, T., Falasca, F., Calabretto, M., Cella, E., Ciccozzi, M., Mezzaroma, I., Iaiani, G., Spaziante, M., d’Ettorre, G., Fimiani, C., Vullo, V., Antonelli, G., & Turriziani, O. (2020). Transmitted drug resistance mutations and trends of HIV-1 subtypes in treatment-naïve patients: A single-centre experience. Journal of Global Antimicrobial Resistance, 20, 298–303.
   PubMed Web of Science ®Google Scholar
• Miller, R. H., & Sarver, N. (1995). HIV accessory proteins: Emerging therapeutic targets. Molecular Medicine, 1(5), 479–485. https://doi.org/10.1007/BF03401585
   PubMed Web of Science ®Google Scholar
• Miyatake, H., Sanjoh, A., Murakami, T., Murakami, H., Matsuda, G., Hagiwara, K., Yokoyama, M., Sato, H., Miyamoto, Y., Dohmae, N., & Aida, Y. (2016). Molecular mechanism of HIV-1 Vpr for binding to importin-α. Journal of Molecular Biology, 428(13), 2744–2757. https://doi.org/10.1016/j.jmb.2016.05.003
   PubMed Web of Science ®Google Scholar
• Morellet, N., Bouaziz, S., Petitjean, P., & Roques, B. P. (2003). NMR structure of the HIV-1 regulatory protein VPR. Journal of Molecular Biology, 327(1), 215–227. https://doi.org/10.1016/s0022-2836(03)00060-3
   PubMed Web of Science ®Google Scholar
• Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., & Olson, A. J. (2009). AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. Journal of Computational Chemistry, 30(16), 2785–2791. https://doi.org/10.1002/jcc.21256
   PubMed Web of Science ®Google Scholar
• Neubert, J., Michalsky, N., Laws, H. J., Borkhardt, A., Jensen, B., & Lübke, N. (2016). HIV-1 subtype diversity and prevalence of primary drug resistance in a single-center pediatric cohort in Germany. Intervirology, 59(5–6), 301–306. https: https://doi.org/10.1159/000477811
   PubMed Web of Science ®Google Scholar
• Rawson, J. M., Landman, S. R., Reilly, C. S., & Mansky, L. M. (2015). HIV-1 and HIV-2 exhibit similar mutation frequencies and spectra in the absence of G-to-A hypermutation. Retrovirology, 12, 60. https: https://doi.org/10.1186/s12977-015-0180-6
   PubMed Web of Science ®Google Scholar
• Scherer, M., Trendelkamp-Schroer, B., Paul, F., Pérez-Hernández, G., Hoffmann, M., Plattner, N., Wehmeyer, C., Prinz, J. H., & Noé, F. (2015). PyEMMA 2: A software package for estimation, validation, and analysis of Markov models. Journal of Chemical Theory and Computation, 11(11), 5525–5542. https://doi.org/10.1021/acs.jctc.5b00743.
   PubMed Web of Science ®Google Scholar
• Schüttelkopf, A. W., & van Aalten, D. M. (2004). PRODRG: A tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallographica. Section D, Biological Crystallography, 60(Pt 8), 1355–1363. https://doi.org/10.1107/S0907444904011679
   PubMedGoogle Scholar
• Shaw, G. M., & Hunter, E. (2012). HIV transmission. Cold Spring Harbor Perspectives in Medicine, 2(11), a006965. https://doi.org/10.1101/cshperspect.a006965
   PubMed Web of Science ®Google Scholar
• Somasundaran, M., Sharkey, M., Brichacek, B., Luzuriaga, K., Emerman, M., Sullivan, J. L., & Stevenson, M. (2002). Evidence for a cytopathogenicity determinant in HIV-1 Vpr. Proceedings of the National Academy of Sciences of the United States of America, 99(14), 9503–9508. https://doi.org/10.1073/pnas.142313699
   PubMed Web of Science ®Google Scholar
• Strebel, K. (2013). HIV accessory proteins versus host restriction factors. Current Opinion in Virology, 3(6), 692–699. https://doi.org/10.1016/j.coviro.2013.08.004
   PubMed Web of Science ®Google Scholar
• The UniProt Consortium. (2021). UniProt: The universal protein knowledgebase in 2021. Nucleic Acids Research, 49(D1), D480–D489. https://doi.org/10.1093/nar/gkaa1100
   PubMed Web of Science ®Google Scholar
• Taylor, B. S., Sobieszczyk, M. E., McCutchan, F. E., & Hammer, S. M. (2008). The challenge of HIV-1 subtype diversity. The New England Journal of Medicine, 358(15), 1590–1602. https://doi.org/10.1056/NEJMra0706737
   PubMed Web of Science ®Google Scholar
• Trott, O., & Olson, A. J. (2010). AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry, 31(2), 455–461.
   PubMed Web of Science ®Google Scholar
• Tuble, C., Anwar, J., & Gale, J. D. (2004). An approach to developing a force field for molecular simulation of martensitic phase transitions between phases with subtle differences in energy and structure. Journal of the American Chemical Society, 126(1), 396–405. https://doi.org/10.1021/ja0356131
   PubMed Web of Science ®Google Scholar
• Venner, C. M., Nankya, I., Kyeyune, F., Demers, K., Kwok, C., Chen, P. L., Rwambuya, S., Munjoma, M., Chipato, T., Byamugisha, J., Van Der Pol, B., Mugyenyi, P., Salata, R. A., Morrison, C. S., & Arts, E. J. (2016). Infecting HIV-1 subtype predicts disease progression in women of Sub-Saharan Africa. EBioMedicine, 13, 305–314. https://doi.org/10.1016/j.ebiom.2016.10.014
   PubMed Web of Science ®Google Scholar
• Wang, C., Nguyen, P. H., Pham, K., Huynh, D., Le, T. B., Wang, H., Ren, P., & Luo, R. (2016). Calculating protein-ligand binding affinities with MMPBSA: Method and error analysis. Journal of Computational Chemistry, 37(27), 2436–2446. https://doi.org/10.1002/jcc.24467
   PubMed Web of Science ®Google Scholar
• Waterhouse, A., Bertoni, M., Bienert, S., Studer, G., Tauriello, G., Gumienny, R., Heer, F. T., de Beer, T. A. P., Rempfer, C., Bordoli, L., Lepore, R., & Schwede, T. (2018). SWISS-MODEL: Homology modelling of protein structures and complexes. Nucleic Acids Research, 46(W1), W296–W303. https://doi.org/10.1093/nar/gky427
   PubMed Web of Science ®Google Scholar
• Wensing, A. M., Calvez, V., Ceccherini-Silberstein, F., Charpentier, C., Günthard, H. F., Paredes, R., Shafer, R. W., & Richman, D. D. (2019). 2019 update of the drug resistance mutations in HIV-1. Topics in Antiviral Medicine, 27(3), 111–121.
   PubMedGoogle Scholar
• Win, N. N., Ngwe, H., Abe, I., & Morita, H. (2017). Naturally occurring Vpr inhibitors from medicinal plants of Myanmar. Journal of Natural Medicines, 71(4), 579–589. https://doi.org/10.1007/s11418-017-1104-7
   PubMed Web of Science ®Google Scholar
• Woo, S., Win, N. N., Wyine, M., Ngwe, H., Ito, T., Abe, I., & Morita, H. (2019). Viral protein R inhibitors from Swertia chirata of Myanmar. Journal of Bioscience and Bioengineering, 128(4), 445–449. https://doi.org/10.1016/j.jbiosc.2019.04.006
   PubMed Web of Science ®Google Scholar
• Wu, Y., Zhou, X., Barnes, C. O., DeLucia, M., Cohen, A. E., Gronenborn, A. M., Ahn, J., & Calero, G. (2016). The DDB1–DCAF1–Vpr–UNG2 crystal structure reveals how HIV-1 Vpr steers human UNG2 toward destruction. Nature Structural & Molecular Biology, 23(10), 933–940. https://doi.org/10.1038/nsmb.3284
   PubMed Web of Science ®Google Scholar
• Xiong, G., Wu, Z., Yi, J., Fu, L., Yang, Z., Hsieh, C., Yin, M., Zeng, X., Wu, C., Lu, A., Chen, X., Hou, T., & Cao, D. (2021). ADMETlab 2.0: An integrated online platform for accurate and comprehensive predictions of ADMET properties. Nucleic Acids Research, 49(W1), W5–W14. https://doi.org/10.1093/nar/gkab255
   PubMed Web of Science ®Google Scholar
• Yang, Z., Wei, S., Liu, J., Piao, J., Xu, L., Sun, Y., Deng, X., Yang, X., Liu, C., Ma, S., Zhao, Q., & Huo, Y. (2020). Characterization of HIV-1 subtypes and drug resistance mutations in Henan Province, China (2017–2019). Archives of Virology, 165(6), 1453–1461. https://doi.org/10.1007/s00705-020-04606-6
   PubMed Web of Science ®Google Scholar
• Zhang, F., & Bieniasz, P. D. (2020). HIV-1 Vpr induces cell cycle arrest and enhances viral gene expression by depleting CCDC137. eLife, 9, e55806. https://doi.org/10.7554/eLife.55806
   Web of Science ®Google Scholar
• Zhao, R. Y., & Bukrinsky, M. I. (2014). HIV-1 accessory proteins: VpR. Methods in Molecular Biology (Clifton, N.J.), 1087, 125–134. https://doi.org/10.1007/978-1-62703-670-2_11
   PubMedGoogle Scholar
• Zhao, R. Y., Li, G., & Bukrinsky, M. I. (2011). Vpr-host interactions during HIV-1 viral life cycle. Journal of Neuroimmune Pharmacology, 6(2), 216–229. https://doi.org/10.1007/s11481-011-9261-z
   PubMed Web of Science ®Google Scholar
• Zheng, X., Gan, L., Wang, E., & Wang, J. (2013). Pocket-based drug design: Exploring pocket space. The AAPS Journal, 15(1), 228–241. https://doi.org/10.1208/s12248-012-9426-6
   PubMed Web of Science ®Google Scholar
• Zotova, A., Atemasova, A., Pichugin, A., Filatov, A., & Mazurov, D. (2019). Distinct requirements for HIV-1 accessory proteins during cell coculture and cell-free infection. Viruses, 11(5), 390. https://doi.org/10.3390/v11050390
   PubMed Web of Science ®Google Scholar